On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.
On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.
In line with the signed AA, the government has adopted a detailed implementation plan, which endorses for preparation and approval by the end of 2015 the concept for a new healthcare system in Ukraine. The concept covers all fields of the healthcare sector, from education and self-government of healthcare professionals to financing public hospitals and reimbursement of the cost of medicinal products and medical devices to patients. Although the concept is still to be elaborated and approved, the reform legislation continues apace, with the long-term goal of establishing a developed and sustainable regulatory framework in Ukraine.
Marketing authorization simplified
On September 5, 2014, Ukraine’s Law on Medicines was amended, adding a category of products subject to simplified marketing authorization procedures. The new procedure applies to medicinal products
The amendments to the Law on Medicines outline the reasons why medicinal products may be denied marketing authorization in Ukraine: 1) submission of incomplete set of documents; 2) incomplete or inaccurate information in the submitted documents; 3) if the manufacturer mentioned in application is different than the manufacturers approved in marketing authorizations for countries with high regulatory standards.
A current draft law (prepared by the Presidents’ Administration, with expert industry input) extends the list of countries considered to have high regulatory standards, adding Australia, New Zealand and Israel. If the draft law is approved (which may happen at the end of October 2014), all medicines authorized in countries with high regulatory standards will be have faster access to Ukraine’s US$3 billion pharmaceutical market.
Reference pricing The government has however introduced stricter pricing limits for medicinal products. Wholesale price change declaration has been mandatory for medicinal products purchased with state funds or included in state pilot programs on reimbursement for several years. However, the previous declaration procedure did not provide any specific restrictions as to the level of wholesale price declared by the marketing authorization holder.
On August 1, 2014, the Procedure for Wholesale Price Calculation for Medicinal Products was approved by the Ministry of Healthcare. Under the new system the MH may not declare the wholesale price at a level higher than the reference price (calculated as simple average of the wholesale prices of respective medicinal products, where the country of origin is Bulgaria, Moldova, Poland, the Slovak Republic, the Czech Republic, Latvia, Hungary, Serbia and Ukraine).
Where there is no general reimbursement system functioning, the introduction of additional pricing restrictions (the government proposed at the drafting stage that reference pricing applied to pharmacy sales of Rx products) seems an unreasonable move on the part of the government. However, given the path toward harmonization with EU laws, stricter pricing in Ukraine can be seen as the first step to the implementation of a comprehensive reimbursement system.
Lana Sinichkina is Partner and Head of Life Sciences and Healthcare, and Leonid Cherniavskyi is Associate at Arzinger Law Office.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.